item management s discussion and analysis of financial condition and results of operations statements included herein which are not historical facts are forward looking statements 
such forward looking statements are made pursuant to the safe harbor provision of the private securities litigation reform act of the forward looking statements involve a number of risks and uncertainties  including but not limited to  changes in economic conditions  demand for the company s products  pricing pressures  intense competition in the industries in which the company operates  the need for the company to keep pace with technological developments and timely respond to changes in customer needs  the company s dependence on third party suppliers  the effect on foreign sales of currency fluctuations  acceptance of new products  the labor relations of the company and its customers and other factors identified in the company s securities and exchange commission filings 
results of operations vs 
for the year ended december   the company had net income of  or 
per diluted share on net sales of  compared with a net loss of  or 
per diluted share on net sales of  for the year ended december  the increase in net sales resulted from increases in both the us and export markets as well as from the company s european subsidiary operations 
sales of shakers  fermentation equipment and ultra low temperature freezers increased  and  respectively  as sales in europe rebounded from a significant downturn which occurred in and from the strong demand for laboratory research equipment in the united states 
while only a small percentage of the company s sales are made directly to united states and foreign government departments and agencies  its business is significantly affected by government expenditures and grants for research to educational research institutions and to industry gross profit for the year ended december  increased to  from  for the increase is due primarily to the increase in net sales as gross margin declined slightly to in from in sales of the company s equipment to foreign companies  institutions and governments may be affected by united states export control regulations 
the company believes that after the september  terrorist attacks  these regulations may be made more restrictive 
selling general and administrative expenses increased modestly to  in from  in the increase was due to normal annual salary and other increases 
research  development and engineering expenses decreased  or due primarily to a reduction in engineering expenses related to the fully custom engineered bioprocess equipment business for which the company ceased accepting orders effective june  custom engineered products had represented a small niche business for the company 
the  of non recurring severance costs incurred in are in connection with the company s withdrawal from this business 
dgi research expenses declined to  in from  in as a result of dgi having received an infusion of funds on june  from an institutional investor  as described below and the fact that dgi s operations were no longer consolidated with those of the company after june   as the company s ownership interest was reduced to and the investment is now accounted for using the equity method 
interest expense decreased to  in from  in due primarily to lower interest rates 
write off of investment decreased from  in to zero in since all of the costs which relate to the company s investment in organica  inc were written off in as a result of carryforward losses related primarily to dgi  income tax expense for represents tax provisions of the company s european subsidiaries  partially offset by a us tax benefit 
the primary reason for the company s effective tax rate of for vs 
the statutory tax rate of was a reduction in the valuation allowance allocated to income tax expense 
equity in operations of dgi resulted in a charge of  in and relates to the company s equity interest in dgi 
the company is not required to  and will not record losses in the future from dgi s operations since it has no further obligations to fund the dgi operations and the carrying value of its investment had been reduced to zero at december  the following table reconciles income before income taxes on an as reported basis with proforma income before income taxes before the effects of dgi  non recurring severance costs in and write off of investment in in thousands such proforma amounts are not intended to be a measurement in accordance with generally accepted accounting principles 
year ended december  income loss before income tax expense benefit and equity in operations of dgi as reported   add dgi research and other expenses   non recurring severance costs write off of investment less dgi revenues proforma  during  the us dollar strengthened against the currencies of the european countries where the company has subsidiary operations 
the effect of balance sheet translation resulted in a currency translation adjustment of  which is reflected as a component of accumulated other comprehensive loss in the equity section of the consolidated balance sheet 
vs 
for the year ended december   the company incurred a net loss of  or 
per diluted share on net sales of  compared with a net loss of  or 
per diluted share on net sales of  for the year ended december  the decrease in net sales in resulted primarily from a decrease in dgi revenues of  from  in to  in  a significant downturn in shipments by the company s european subsidiaries as a result of the continued strength of the us dollar against currencies in the countries where the company s european subsidiaries operate and what management believes to be a short term weakening in the european market 
in addition  the sale of a large custom bioprocess system in europe in the amount of  was included in sales with no comparable sale in no tax benefit was recognized for the company s us operating losses which are primarily attributable to losses incurred by the company s majority owned drug lead discovery operation  dgi biotechnologies dgi 
gross margins increased to in from in inclusive of dgi revenues against which there is no cost of sales  and 
excluding dgi revenues from the and periods  gross margins increased to in from in  primarily as a result of the company s acquisition of djm cryo research in november  which prior to the acquisition was a supplier to the company 
in addition  in the company benefited from a more profitable mix of products sold than in selling  general and administrative expenses remained relatively flat at  in and  in during  the company did not incur any significant increases to its selling  general and administrative expenses and made some reductions in order to offset normal inflationary increases in salaries and other expenses 
research  development and engineering expenses increased  or to  dgi  in from  dgi  in primarily as the result of an increase in costs to support the research efforts of dgi  the company s drug lead discovery operation whose expenses increased to  in from  in also contributing to the increase were expenses of djm which was acquired in november  and consequently not included in the company s results of operations for most of and additional costs incurred during to strengthen the company s engineering staff 
non recurring severance costs decreased from  to zero as all such costs were accrued at december  interest expense increased to  in compared with  for as a result of borrowings under the company s bank agreement for the acquisition of djm in november and for working capital purposes 
the  write off of the company s investment in organica  inc during is a result of a permanent impairment of its investment in organica as described in item business  investment in organica  inc in the company s annual report on form k for the year ended december   and in other matters  below 
other expense  net was  in and  in due primarily to the disposal of fixed assets and the company s equity loss in a joint venture entered into in during  the us dollar strengthened against the currencies of the european countries where the company has subsidiary operations 
the effects of balance sheet translation resulted in a currency translation adjustment of  which is reflected as a component of accumulated other comprehensive loss in the equity section of the consolidated balance sheet 
financial condition liquidity and capital resources working capital increased to  at december  from   at december  and cash and cash equivalents increased to  from  at december  accounts receivable increased to  at december  from  at december  due primarily to an increase in sales in the fourth quarter of compared with the fourth quarter of inventories decreased to  at december  from  at december  primarily as a result of a significant decrease in inventory related to fully custom engineered bioprocess systems for which the company ceased accepting orders at the end of june current installments of long term debt decreased to  at december  from  at december  due to the reclassification to non current of the company s bank debt 
the bank agreement  which was due to mature on may   was amended on march  to extend its maturity date to may  other liabilities increased to  at december  from  at december  primarily as a result of a significant increase in the minimum pension liability adjustment 
on april   the company entered into an agreement the bank agreement with first union national bank for a three year  million secured line of credit 
the bank agreement provides the company with a million revolving credit facility for both working capital and for letters of credit  a million revolving line of credit for equipment acquisition purposes  a million credit line for acquisitions and a million foreign exchange facility 
there are no compensating balance requirements and any borrowings under the bank agreement bear interest at various rates based upon a function of the bank s prime rate or libor at the discretion of the company 
all of the company s domestic assets  which are not otherwise subject to lien  have been pledged as security for any borrowings under the bank agreement 
the bank agreement contains various business and financial covenants including among other things  a debt service coverage ratio  a net worth covenant  and a ratio of total liabilities to tangible net worth 
the company was not in compliance with certain financial covenants at december  and march  which non compliance was waived by the bank 
on may  and on november   the financial covenants were amended and  as a result  the company is in compliance with the amended covenants at december  and expects to be in compliance for the ensuing twelve months 
at december    was outstanding under the bank agreement related to working capital and acquisition loans   was being utilized for letters of credit and foreign exchange transactions and the following amounts were available  for working capital and letters of credit   for equipment acquisitions   for acquisitions and  under the foreign exchange facility 
on march   the bank agreement  which was due to mature on may  was amended to extend its maturity date to may  in november  the company issued notes in the amount of   at the date of acquisition in connection with the acquisition of the djm cryo research group 
the notes bear interest at which are payable annually and principal is payable in five equal annual installments commencing november at december  the balance due on the notes was  the company s contractual obligatons and commitments principally include obligations associated with its outstanding indebtedness and future minimum operating lease obligations as set forth in the following table payments due by period in thousands contractual obligations within after total year years years years long term debt  notes and credit facility   operating leases   total contractual cash obligations     drug lead discovery business in october  the company entered the drug lead discovery business by forming a new company to develop a novel  small molecule drug discovery platform 
the company  dgi biotechnologies  inc dgi  was majority owned and fully funded by the company and occupies specially designed laboratory space at the company s headquarters facility in edison  new jersey 
dgi s operations have had a significant negative impact on the company s and earnings 
during the year ended december  and   and  respectively  of research and development expenses were charged to operations resulting in operating losses related to dgi of  in and  in on june  an institutional investor invested  in dgi in exchange for series b voting convertible preferred stock of dgi 
the series b convertible preferred stock of dgi has certain dividend  liquidation and other rights senior to the series a preferred stock of dgi held by the company 
this transaction reduced the company s ownership interest in dgi to 
accordingly  effective june   as required by accounting principles generally accepted in the united states of america  the company no longer exercises control and ceased consolidating the operations of dgi but reports its percentage of income or loss in dgi s operations on the equity method of accounting based upon its continued ability to exercise significant influence over dgi 
the company is not required to  and has not recorded losses from its share of dgi s operations beyond the carrying value of its investment since it has no further obligations to fund the dgi operations 
as of december   the carrying value of the company s investment in dgi had been reduced to zero 
the company has entered into a two year lease with dgi under which dgi occupies  square feet of office and specifically designed laboratory space at the company s headquarters facility in edison  new jersey for a gross rental of  per year 
under the terms of the lease  dgi has the right to cancel upon providing the company with days notice 
the lease was established at arm s length utilizing market value information 
cash flows from operating activities net cash provided by operating activities was  in compared with net cash used in operating activities of  in net cash provided by operating activities in was composed of net income of  adjusted for depreciation and amortization and equity in operations of dgi which are non cash items aggregating  and net cash used for changes in operating assets and liabilities of  which are primarily attributable to an increase in accounts receivable due to the high level of shipments late in the year and a substantial reduction in other assets directly related to the reduction in the valuation allowance against the deferred tax asset due to the significant improvement in the company s operating income  offset by a decrease in inventories partly attributable to the company s decision to stop accepting orders for large fully custom engineered bioprocess equipment 
net cash used in operating activities of  in resulted primarily from the net loss of  adjusted for non cash charges of  for depreciation and amortization and  for the write off of an investment and net cash provided by changes in operating assets and liabilities of  which are primarily attributable to a decrease in accounts receivable due to a lower level of shipments in and an increase in advance payments from customers offset by an increase in inventories and a decrease in accounts payable and accrued expenses 
cash flows from investing activities net cash used in investing activities amounted to  in compared with  in both years included expenditures for property  plant and equipment and included  of additional goodwill related to acquisition costs of djm cryo research 
cash flows from financing activities net cash used in financing activities amounted to  in compared with net cash provided of  in both years reflect the scheduled repayment of long term debt  proceeds under stock purchase and option plans   and proceeds from notes receivable related to exercised stock options  
also reflects a million repayment under the company s revolving credit facility 
management believes that the resources available to the company  including current cash and cash equivalents  cash generated from operations and its line of credit which matures may   will satisfy its expected working capital needs and capital expenditures for the near and intermediate term 
other matters significant accounting policies revenue recognition revenue is recognized when products are shipped 
the company s products are tested by its quality control department prior to shipment 
the company has no other obligation associated with its products once shipment has occurred except for customary warranty provisions 
historically  returns have been immaterial to the company s consolidated financial statements and are projected to remain at a consistent immaterial level in the future 
the company reports all amounts billed to customers related to shipping and handling as revenue and includes all costs incurred for shipping and handling as cost of sales 
recently issued accounting standards in july  the fasb issued statement no 
 business combinations sfas and statement no 
 goodwill and other intangible assets sfas 
sfas requires that the purchase method of accounting be used for all business combinations completed after june  sfas also specifies the criteria that intangible assets acquired in a purchase method business combination must meet to be recognized and reported apart from goodwill 
sfas requires that goodwill and intangible assets with indefinite useful lives no longer be amortized  but instead they will be tested for impairment at least annually in accordance with the provisions of sfas sfas also requires that intangible assets with definite useful lives be amortized over their respective estimated useful lives to their estimated residual values  and reviewed for impairment in accordance with sfas no 
 accounting for the impairment of long lived assets and for long lived assets to be disposed of 
the company is required to adopt the provisions of sfas for acquisitions initiated after june   and sfas effective january  goodwill and intangible assets acquired in business combinations completed before july  have been amortized through december  sfas requires that the company perform an assessment of whether there is an indication that goodwill is impaired based on the provisions of sfas to the extent an indication exists that the goodwill may be impaired  the company must measure the impairment loss  if any 
the company has completed its assessment and has determined that there is no impairment to its goodwill balance of  as of december  amortization expense related to goodwill was  and  for the years ended december  and  respectively 
after december   the company will no longer be amortizing goodwill 
the company has adopted the provisions of sfas effective january  and the results of the adoption have had no effect on its consolidated financial statements 
impact of terrorist activities and responses the company cannot assess at this time whether the terrorist attacks on september  and subsequent terrorist activities or the response of the united states and foreign governments to those attacks and activities will have any specific impact on the company 
the company notes that its equipment is used by pharmaceutical and biotechnology companies in the development of vaccines and antibiotics 
sales of the company s equipment to foreign companies  institutions and governments may be affected by united states export control regulations 
the company believes that after the september  terrorist attacks  these regulations may be made more restrictive 
investment in organica  inc beginning in november  the company invested  less than a twenty percent voting interest in organica  inc organica which was formed in to develop and commercialize various environmentally friendly products produced via fermentation processes 
as previously described in the company s prior year annual report on form k  there had been continuing uncertainties as to the future direction of organica  inc as it continued to generate losses 
the company concluded that a portion of its investment in organica  inc had become permanently impaired and recorded an  writedown in the second quarter of to reduce its investment balance to  the then estimated recoverable amount 
subsequently  the two members of the organica board of directors appointed by the company resigned 
on october  organica filed in the united states bankruptcy court for the district of delaware  a voluntary petition for reorganization under chapter of the bankruptcy code 
based on the information available at that time  the company determined that the investment was not recoverable and  accordingly  wrote off the remaining  investment in the third quarter of quantitative and qualitative disclosures about market risk in the normal course of business  the company is exposed to fluctuations in interest rates as it seeks debt financing to make capital expenditures  potential acquisitions  and invest in cash equivalents and marketable debt securities 
cash equivalents and other marketable investments are carried at fair value on the consolidated balance sheets 
at times  management employs specific strategies  such as the use of derivative instruments or hedging to manage foreign currency or other exposures 
further  the company does not expect its market risk exposures to change in the near term 

